CN106551936A - One kind treats rhinitis medicine and its application - Google Patents
One kind treats rhinitis medicine and its application Download PDFInfo
- Publication number
- CN106551936A CN106551936A CN201611026404.3A CN201611026404A CN106551936A CN 106551936 A CN106551936 A CN 106551936A CN 201611026404 A CN201611026404 A CN 201611026404A CN 106551936 A CN106551936 A CN 106551936A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- fistulains
- medicine
- treatment
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to field of medicaments, specifically related to a kind of medicine for the treatment of rhinitis, it is made up of compound Fistulains A and adjuvant, clear curative effect, belong to first public, as framework types belong to brand-new framework types, and its treatment rhinitis activity is strong, possess prominent substantive distinguishing features, while the preventing and treating for rhinitis obviously has significant progress.
Description
Technical field
The present invention relates to the new application of compound Fistulains A, more particularly to Fistulains A are in preparation treatment nose
Application in scorching medicine.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is mainly relevant with anaphylaxiss, belongs to immune inflammation
Category.At present, rhinitis is treated mainly using antiallergic agents such as antihistamine drug or tranilast, ketotifen such as teldanes
Thing, these medicines are poor or invalid to the chronicity and recurrent exerbation curative effect of rhinitis.Therefore, definite ingredients, quality controllable and peace
Complete efficient micromolecular compound is worth with potential in terms for the treatment of of rhinitis medicine is developed.
Compound Fistulains A according to the present invention be one deliver within 2015 (Min Zhou, et al.,
Fistulains A and B,New Bischromones from the Bark of Cassia f istula,and
Their Activities.Org.Lett.2015,17,2638-2641.) noval chemical compound, the compound possess brand-new bone
Frame type, is only resistant to TMV virus (Min Zhou, et al., Fistulains A and B, New Bischromones from
the Bark of Cassia f istula,and Their Activities.Org.Lett.2015,17,2638-
2641.), purposes of the Fistulains A according to the present invention in treatment rhinitis medicine is prepared belongs to first public.
The content of the invention
It is an object of the invention to provide a kind of anti-rhinitis medicament thing and its application.
One kind treats rhinitis medicine, is made up of compound Fistulains A and adjuvant, the compound Fistulains
A structures are as shown in formula I：
The treatment rhinitis medicine, adjuvant is dextrin or starch.
Application of the treatment rhinitis medicine in treatment rhinitis medicine is prepared.
Compound Fistulains A 10,20mg/kg oral administrations, to rat caused by antigen (ovalbumin) and histamine
Scratch nose, sneeze reaction and nasal cavity vascular permeability raise it is inhibited, therefore, can be used to prepare treatment rhinitis
Medicine.Purposes of the Fistulains A in treatment rhinitis medicine is prepared belongs to first public, as framework types belong to brand-new
Framework types, and its treatment rhinitis activity is strong, possesses prominent substantive distinguishing features, while the preventing and treating for rhinitis obviously has
There is significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by concrete real
Any restriction of example is applied, but is defined in the claims.
Specific embodiment
The preparation method of compound Fistulains A involved in the present invention referring to document (Min Zhou, et al.,
Fistulains A and B,New Bischromones from the Bark of Cassia f istula,and
Their Activities.Org.Lett.2015,17,2638-2641.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by concrete real
Any restriction of example is applied, but is defined in the claims.
Embodiment 1：The preparation of compound Fistulains A tablets involved in the present invention：
5 g of compound Fistulains A are taken, 195 grams of dextrin is added, is mixed, Conventional compression makes 1000.
Embodiment 2：The preparation of compound Fistulains A capsules involved in the present invention：
5 g of compound Fistulains A are taken, 195 grams of starch is added, is mixed, it is encapsulated to make 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example 1, Fistulains A of the present invention cause the impact of rat allergic rhinitises to ovalbumin
Male SD rat, 180～220g of body weight, lumbar injection ovalbumin 1mg and gel aluminum hydroxide 10mg, thereafter every
Day injection 1 time, totally 7 times.Began from the 14th day, 1mg/ml ovalbumin normal saline solutions are instilled in rat both sides nasal cavity daily
10ul, totally 7 times.Last observes the number of times of rat sneeze and wiping nose in 30 minutes at once after instiling, trial drug is in white of an egg egg
White last instils and orally gives within first 1 hour (prepare by 1 method of above-described embodiment).
1 Fistulains A of the present invention of table cause the impact (x ± SD) of rat allergic rhinitises to ovalbumin
Compare with matched group, * * P<0.01 *P<0.05
From table 1, Fistulains A (10,20mg/kg) substantially suppress allergic rhinitises rat caused by ovalbumin
Sneeze and scratch nose reaction.Teldane 10mg/kg is also presented significant inhibitory action.
The impact of the rat rhinitis that experimental example 2, Fistulains A of the present invention cause to histamine
Male SD rat, 180～220g of body weight are orally given 1 hour after trial drug, and both sides nasal cavity instills 1M histamine
Normal saline solution 10ul, observes the number of times of rat sneeze and wiping nose in 30 minutes.
2 Fistulains A of the present invention of table cause the impact (x ± SD) of rat rhinitis to histamine
Compare with matched group, * * P<0.01*P<0.05
From table 2, Fistulains A (10,20mg/kg) of the present invention significantly reduce the spray of rhinitis rat caused by histamine
Number of times is sneezed, to nose reaction of scratching in suppression trend.Teldane 10mg/kg is in then significant inhibitory action.
Conclusion：Fistulains A oral administrations, nose of scratching to rat caused by antigen (ovalbumin) and histamine, play spray
Sneeze reaction inhibited, therefore, can be used to prepare the medicine for the treatment of rhinitis.
Claims (3)
1. one kind treats rhinitis medicine, it is characterised in that be made up of compound Fistulains A and adjuvant, the compound
Fistulains A structures are as shown in formula I：
2. rhinitis medicine is treated as claimed in claim 1, it is characterised in that adjuvant is dextrin or starch.
3. application of the treatment rhinitis medicine in treatment rhinitis medicine as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611026404.3A CN106551936A (en) | 2016-11-18 | 2016-11-18 | One kind treats rhinitis medicine and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611026404.3A CN106551936A (en) | 2016-11-18 | 2016-11-18 | One kind treats rhinitis medicine and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106551936A true CN106551936A (en) | 2017-04-05 |
Family
ID=58444508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611026404.3A Withdrawn CN106551936A (en) | 2016-11-18 | 2016-11-18 | One kind treats rhinitis medicine and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106551936A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872034A (en) * | 2012-10-26 | 2013-01-16 | 吴俊华 | Application of Gypensapogenin B in medicaments for treating rhinitis |
| CN103463007A (en) * | 2013-10-10 | 2013-12-25 | 段仲达 | Application of racemosins A in preparation of medicine treating rhinitis |
| CN105294720A (en) * | 2015-05-08 | 2016-02-03 | 云南民族大学 | Dimerization chromone alkaloid compound as well as preparation method and application thereof |
-
2016
- 2016-11-18 CN CN201611026404.3A patent/CN106551936A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872034A (en) * | 2012-10-26 | 2013-01-16 | 吴俊华 | Application of Gypensapogenin B in medicaments for treating rhinitis |
| CN103463007A (en) * | 2013-10-10 | 2013-12-25 | 段仲达 | Application of racemosins A in preparation of medicine treating rhinitis |
| CN105294720A (en) * | 2015-05-08 | 2016-02-03 | 云南民族大学 | Dimerization chromone alkaloid compound as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106551936A (en) | One kind treats rhinitis medicine and its application | |
| CN103585150B (en) | Use of Nitrosporeusines A in drugs for treating rhinitis | |
| CN105362274A (en) | Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals | |
| EP3977989A1 (en) | Composition for the treatment of novel corona virus disease (covid-19) | |
| CN102872034B (en) | Application of Gypensapogenin B in medicaments for treating rhinitis | |
| CN105125533A (en) | Medicine for treating rhinitis and application thereof | |
| CN106389404A (en) | Applications of Linderolide H in preparing medicines for treating rhinitis | |
| CN103494826B (en) | The application of Phyllanthoid A in preparation treatment rhinitis medicine | |
| CN105287545A (en) | Applications of Strynuxlines A in preparation of rhinitis treatment drugs | |
| CN101155581A (en) | Medicament and treatment for herpes simplex | |
| CN105456246A (en) | Application of Lathyranone A in preparation of drug for treating rhinitis | |
| CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
| CN103330712A (en) | Application of Myriberine A in preparation of a medicine for treating rhinitis | |
| CN105287495A (en) | Application of Sphenostylisins C in preparation of drugs used for treating rhinitis | |
| CN103393699B (en) | The application of Chukrasone A in preparation treatment rhinitis medicine | |
| CN103372006B (en) | The application of Chukrasone B in preparation treatment rhinitis medicine | |
| CN103751170B (en) | The application of Trigoxyphin K in treatment rhinitis medicine | |
| CN107865862A (en) | Apigenin is preparing the application in treating rhinitis medicine | |
| CN107865846A (en) | Isovitexin is preparing the application in treating rhinitis medicine | |
| CN109646438A (en) | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug | |
| CN102614252B (en) | Prescription for treating cataract | |
| CN102988390B (en) | Application of Houttuynoid C for preparing medicine for treating rhinitis | |
| CN103127078A (en) | Application of Aphanamixoid A to rhinitis treatment medicine | |
| CN102988393B (en) | Application of Houttuynoid B for preparing medicine for treating rhinitis | |
| CN103585152A (en) | Application of Caesanines D in medicament for treating rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170405 |